Morgan Stanley resumed coverage of Royalty Pharma (RPRX) with an Overweight rating and $51 price target The firm cites se the company’s diversified portfolio and insulation from potential tariffs, coupled with a growth profile above the peer average, as positives.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RPRX: